BIOGEN INC.
Last · NasdaqGS$232.83+3.93 (+1.72%)close · yahoo · 7h ago
Market cap$34.40B147.8M sh
P/E · TTM41.4fwd 14.1 · eps 5.63
Beta0.09vs S&P 500
Div yield0.00%annual · TTM
52w range
$138.00$238.24
Volume1.9Msession
| Revenue | $10.0B |
|---|---|
| Operating income | $510.1M |
| Net income | $417.0M |
| Free cash flow | $2.7B |
| Operating margin | 5.1% |
| Net margin | 4.2% |
| Return on equity | 2.2% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-06
- Ms Revenue Decline
- TecიფIdera Generic Erosion
- Tysabri Biosimilar
- Ira Drug Pricing
- Rare Disease Growth
- Manufacturing Capacity
- China Supplier Exposure
Red flags
- MS product revenue fell $310.9 million, or 7.1%, in 2025, while TECFIDERA faces multiple generic entrants and TYSABRI faces biosimilar competition.
- Diluted EPS fell 21.4% year over year despite 2.2% total-revenue growth, indicating material earnings pressure beneath the modest top-line increase.
- Certain SKYCLARYS starting materials rely on a single supplier based in China, creating tariff, geopolitical and continuity exposure.
- TYSABRI carries royalties of 18.0% of annual worldwide net sales up to $2.0 billion and 25.0% above that level; SPINRAZA and QALSODY royalties are 11.0%-15.0%, and VUMERITY royalties are 15.0%-16.0%.
- Biogen issued $1.75 billion of senior notes in 2025, including debt carrying coupons of 5.050%-6.450%, increasing interest burden while the portfolio is transitioning.
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$2.03
Est. revenue
2.6B
Earnings transcripts
Press & signals
- GlobeNewswire
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- GlobeNewswire
Biogen Completes Acquisition of RayThera Inc.
- GlobeNewswire
Biogen Appoints Michael J. Parini as Chief Legal Officer